Drugs / [Ga-68]-PNT6555
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05432193 | Jul 2022 → Nov 2023 | cholangiocarcinoma, colorectal cancer, cutaneous melanoma, esophageal cancer +3 | POINT Biopharma | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [Ga-68]-PNT6555 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05432193 ↗ |
| Modality | Diagnostic / imaging agent | “administered as imaging agent for PET/CT” NCT05432193 ↗ |
| Route | Intravenous | “IV administered as imaging agent for PET/CT” NCT05432193 ↗ |